Filtered By:
Procedure: Kidney Transplant
Therapy: Dialysis

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 122 results found since Jan 2013.

Time-averaged level of fibroblast growth factor-23 and clinical events in chronic kidney disease
Conclusions Our study confirms that FGF23 is an important cardiovascular risk factor. Two measurements of FGF23 have no added value over a single value to predict the cardiovascular outcome. This study demonstrates that, under routine clinical practice, the variability of FGF23 in 2 years' time is small. Concomitantly, this study showed no benefit of consecutive FGF23 testing for estimating the risk of a clinical event in an individual patient.
Source: Nephrology Dialysis Transplantation - January 10, 2014 Category: Urology & Nephrology Authors: Bouma-de Krijger, A., Bots, M. L., Vervloet, M. G., Blankestijn, P. J., ter Wee, P. W., van Zuilen, A. D., Wetzels, J. F. Tags: Chronic Kidney Disease Source Type: research

Risk of intracranial hemorrhage associated with autosomal dominant polycystic kidney disease in patients with end stage renal disease
Conclusions: ADPKD is a significant risk factor for ICH among patients on maintenance dialysis. Our Medicare primary cohort was older than in previous studies of intracranial aneurysm rupture among ADPKD patients. There are also limitations inherent to using the USRDS database.
Source: BioMed Central - February 26, 2014 Category: Journals (General) Authors: David J YooLawrence AgodoaChristina M YuanKevin C AbbottRobert Nee Source Type: research

Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial
Conclusions Among maintenance dialysis patients with hypertension and left ventricular hypertrophy, atenolol-based antihypertensive therapy may be superior to lisinopril-based therapy in preventing cardiovascular morbidity and all-cause hospitalizations. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases; ClinicalTrials.gov number: NCT00582114)
Source: Nephrology Dialysis Transplantation - February 28, 2014 Category: Urology & Nephrology Authors: Agarwal, R., Sinha, A. D., Pappas, M. K., Abraham, T. N., Tegegne, G. G. Tags: Intra- and Extracorporeal Treatments of Kidney Failure Source Type: research

Cardiovascular Risk Assessment Before and After Kidney Transplantation
Cardiovascular disease (CVD) is the leading cause of death in dialysis patients and the most common cause of death and allograft loss among kidney transplant recipients. End-stage renal disease (ESRD) is associated with an increased incidence and prevalence of a wide range of CVDs including coronary artery disease, stroke, congestive heart failure, atrial fibrillation, sudden cardiac death, pulmonary hypertension, and valvular heart disease. CVD risk factors are very common in patients with ESRD, and most patients have multiple risk factors. Kidney transplantation is the treatment of choice for patients with ESRD, as a suc...
Source: Cardiology in Review - June 6, 2014 Category: Cardiology Tags: Review Articles Source Type: research

SuO029 * THE RISK OF STROKE IN END-STAGE KIDNEY DISEASE: A COHORT STUDY OF 10,745 PEOPLE
Source: Nephrology Dialysis Transplantation - May 21, 2015 Category: Urology & Nephrology Authors: Masson, P., Kelly, P. J., Craig, J. C., Lindley, R. I., Webster, A. C. Tags: REGISTRIES Source Type: research

Fp332 * risk factors for stroke in people with end-stage kidney disease: a cohort study of 10,745 people
Source: Nephrology Dialysis Transplantation - May 21, 2015 Category: Urology & Nephrology Authors: Masson, P., Kotwal, S., Kelly, P. J., Craig, J. C., Lindley, R. I., Gallagher, M., Cass, A., Webster, A. C. Tags: CHRONIC KIDNEY DISEASE. CLINICAL EPIDEMIOLOGY - 1 Source Type: research

Sp372 * increased risk of ischemic stroke in patients with chronic kidney disease after recurrent dysnatremia: a nationwide population based cohort study in taiwan
Source: Nephrology Dialysis Transplantation - May 21, 2015 Category: Urology & Nephrology Authors: Chung, M.-C., Yu, T.-M., Wu, M.-J., Chang, C.-H., Muo, C.-H., Shu, K.-H., Chen, H.-W., Chung, C.-J. Tags: CHRONIC KIDNEY DISEASE. CLINICAL EPIDEMIOLOGY - 2 Source Type: research

Sp378 * does the presence of chronic kidney disease influence haemorrhagic stroke outcomes?
Source: Nephrology Dialysis Transplantation - May 21, 2015 Category: Urology & Nephrology Authors: Thomas, P., Carr, P., Sandler, D., Baharani, J. Tags: CHRONIC KIDNEY DISEASE. CLINICAL EPIDEMIOLOGY - 2 Source Type: research

Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients
Conclusions In incident HD patients, ferumoxytol showed similar short- to mid-term safety profiles with regard to cardiovascular, infectious and mortality outcomes compared with the more commonly used intravenous iron formulations IS and FG.
Source: Nephrology Dialysis Transplantation - November 23, 2015 Category: Urology & Nephrology Authors: Airy, M., Mandayam, S., Mitani, A. A., Chang, T. I., Ding, V. Y., Brookhart, M. A., Goldstein, B. A., Winkelmayer, W. C. Tags: Intra- and extracorporeal treatments of kidney failure Source Type: research

Early versus delayed erythropoietin for the anaemia of end-stage kidney disease.
CONCLUSIONS: We found no evidence to assess the benefits and harms of early versus delayed EPO for the anaemia of ESKD. PMID: 26671531 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - December 16, 2015 Category: Journals (General) Authors: Coronado Daza J, Martí-Carvajal AJ, Ariza García A, Rodelo Ceballos J, Yomayusa González N, Páez-Canro C, Loza Munárriz C, Urrútia G Tags: Cochrane Database Syst Rev Source Type: research

Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial
Background Blood pressure (BP) control and reduction of urinary protein excretion using agents that block the renin–angiotensin aldosterone system are the mainstay of therapy for chronic kidney disease (CKD). Research has confirmed the benefits in mild CKD, but data on angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) use in advanced CKD are lacking. In the STOP-ACEi trial, we aim to confirm preliminary findings which suggest that withdrawal of ACEi/ARB treatment can stabilize or even improve renal function in patients with advanced progressive CKD. Methods The STOP-ACEi trial (tri...
Source: Nephrology Dialysis Transplantation - January 25, 2016 Category: Urology & Nephrology Authors: Bhandari, S., Ives, N., Brettell, E. A., Valente, M., Cockwell, P., Topham, P. S., Cleland, J. G., Khwaja, A., El Nahas, M. Tags: Chronic Kidney Disease Source Type: research

The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease
Abstract Chronic kidney disease (CKD) anemia treatment was revolutionized in the late 1980s with the introduction of recombinant human erythropoietin. This and related erythropoiesis-stimulating agents (ESAs) greatly benefited patients by decreasing debilitating symptoms, improving their quality of life, and freeing them from dependence on blood transfusions with their associated complications such as infections, sensitization impeding transplantation, and secondary iron overload. However, even in the initial studies, untoward effects were noted in patients receiving ESAs, including worsening hypertension, seizure...
Source: Clinical Drug Investigation - February 19, 2016 Category: Drugs & Pharmacology Source Type: research

Effects of blood pressure on renal and cardiovascular outcomes in Asian patients with type 2 diabetes and overt nephropathy: a post hoc analysis (ORIENT-blood pressure)
Conclusion In Asian type 2 diabetic patients with chronic kidney disease and heavy proteinuria, reduction of SBP ≤ 130 mmHg was associated with greater renoprotection than cardioprotection. However, our results emphasize the need to individualize BP targets in type 2 diabetes.
Source: Nephrology Dialysis Transplantation - February 22, 2016 Category: Urology & Nephrology Authors: Imai, E., Ito, S., Haneda, M., Harada, A., Kobayashi, F., Yamasaki, T., Makino, H., Chan, J. C. N. Tags: Chronic Kidney Disease Source Type: research

APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans
Conclusions Greater numbers of APOL1 G1/G2 risk alleles were associated with higher small HDL particle concentrations in African Americans. These results may suggest novel areas of investigation to uncover reasons for the association between APOL1 risk variants with adverse outcomes in African Americans.
Source: Nephrology Dialysis Transplantation - March 22, 2016 Category: Urology & Nephrology Authors: Gutierrez, O. M., Judd, S. E., Irvin, M. R., Zhi, D., Limdi, N., Palmer, N. D., Rich, S. S., Sale, M. M., Freedman, B. I. Tags: Chronic Kidney Disease Source Type: research

Defining end-stage renal disease in clinical trials: a framework for adjudication
Unlike definition of stroke and myocardial infarction, there is no uniformly agreed upon definition to adjudicate end-stage renal disease (ESRD). ESRD remains the most unambiguous and clinically relevant end point for clinical trialists, regulators, payers and patients with chronic kidney disease. The prescription of dialysis to patients with advanced chronic kidney disease is subjective and great variations exist among physicians and countries. Given the difficulties in diagnosing ESRD, the presence of estimated GFR <15 mL/min/1.7 3m2 itself has been suggested as an end point. However, this definition is still a surrog...
Source: Nephrology Dialysis Transplantation - May 22, 2016 Category: Urology & Nephrology Authors: Agarwal, R. Tags: IDEAS, CONJECTURES AND REFUTATIONS Source Type: research